Total Funding
44
44
Total FundingVenture - Series Unknown raised
Growth Score
-2 pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
124661
Aurum Biosciences has develops novel pharmaceuticals for use in a number of different clinical indications of high unmet medical need.
- Jim McGuire: CEOPast Role: Clear Surgical, CEO and Founder
- Graeme Deuchar: R&D Director
About the Company
AURUM Biosciences Ltd develops novel pharmaceuticals for use in a number of different clinical indications of high unmet medical need. Aurum is currently completing preclinical development of ABL101, its lead stroke management product, and envisages initiating clinical studies of efficacy and safety in the near future. Follow-on programmes include
products for heart disease, cancer, epilepsy, and dementia. Aurum’s lead project utilises an oxygen carrier and proprietary software for use with MRI in Acute Ischaemic Stroke. Aurum has funding in place to initiate recruitment for a Phase 2 clinical study in stroke patients.
